As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize ... which are then distributed to more than 50 countries worldwide.

Tokyo District Court on Wednesday sentenced a former employee of drugmaker Daiichi Sankyo to 16 years in prison ... the use of methanol in the case was "more difficult to detect than other killing ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID ... insider access to events and more.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global ... over the next 10 years as we expect further approvals in more regions and earlier lines of treatment. Additionally, strong ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca ... massage, counseling and more. Those services may help patients “manage side effects and symptoms, adhere to treatments better ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan ...

Recommended Reading AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors An experimental medicine from AstraZeneca and Daiichi Sankyo failed to help people with a common form ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The drug, which is named Datopotamab deruxtecan (Dato-DXd), was jointly developed by the British-Swedish group and Japanese ...

Daiichi Sankyo will seek to maintain its edge over ... In a time of both misinformation and too much information, quality journalism is more crucial than ever. By subscribing, you can help us ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by ...